Revolutionizing AFib treatment with a dual-energy platform for personalized care.
Johnson & Johnson MedTech has earned CE mark approval for its Dual Energy ThermoCool SmartTouch SF catheter, designed to deliver tailored cardiac ablation procedures using both radiofrequency (RF) and pulsed field (PF) energy.
Key Features of the Dual Energy Catheter
- Energy Duality: Offers seamless switching between RF and PF energy, allowing for customized treatment based on patient-specific needs.
- Advanced Compatibility: Fully integrates with the Carto 3 system for precise electro-anatomical mapping and tag indexing.
- Efficient Design: Features an irrigated, contact-force sensing mechanism powered by the TruPulse generator (expected hardware compatibility in H1 2025).
A New Era in AFib Care
The catheter addresses the growing need for flexible and precise tools in treating atrial fibrillation (AFib):
- Enables electrophysiologists to tailor treatments to unique patient anatomies.
- Combines the thermal accuracy of RF energy with the tissue-selective advantages of PF energy.
- Enhances procedural outcomes with a point-by-point ablation workflow.
Dr. Tom De Potter, a leading electrophysiologist, emphasized the impact:
“The ability to use both RF and PF energy in one catheter allows for more effective and targeted procedures, leading to improved patient outcomes.”
The Road Ahead
While the catheter is currently available in Europe, U.S. approval efforts are ongoing. Johnson & Johnson MedTech continues to advance its mission to equip electrophysiologists with innovative tools for treating complex cardiac conditions.
Jasmina Brooks, President of Electrophysiology, highlighted the significance:
“This dual-energy solution empowers physicians to deliver safer, more effective treatments while meeting the growing demand for personalized care.”
Stay tuned with MEDWIRE.AI for the latest breakthroughs in electrophysiology and medical innovation worldwide.
